GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Net Income (Discontinued Operations)

Chemomab Therapeutics (STU:2QV0) Net Income (Discontinued Operations) : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Chemomab Therapeutics's Net Income (Discontinued Operations) for the three months ended in Sep. 2024 was €0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Chemomab Therapeutics Net Income (Discontinued Operations) Historical Data

The historical data trend for Chemomab Therapeutics's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Net Income (Discontinued Operations) Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income (Discontinued Operations)
- - - -

Chemomab Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Chemomab Therapeutics Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
BCDA TMBR VRPX BCEL CNSP BRTX SIGY MNPR MRZM PCSA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CMMB:USA
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Website
https://www.chemomab.com
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines